On February 1, 2023 BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be reported its results for the fourth quarter 2022 on Thursday 16 February 2023. The briefing will take place at 10:00 am CET at (Press release, BerGenBio, FEB 1, 2023, View Source [SID1234626698]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Carnegie AS, Fjordalleen 16, Aker Brygge, 5th Floor, Oslo
where BerGenBio’s senior management team will provide an update on the Company
followed by a Q&A session. To attend in person please register by mail to
[email protected]
The presentation will webcast live and a link will be available at www.bergenbio.com in the Investors/Financial Reports section and a recording will be available shortly after the webcast has finished.
The fourth quarter financial report and presentation will be made available on the Company’s website in the Investors/Financial Reports section from 7:00am CET the same day.